Share the post "The Impact of Global Events of Foriegn Investments on 15 Jul 2024"
Foreign Investment(buy/sell) Trends of 15 Jul 2024: Global Events on Kellton Tech Solutions Ltd., JUBILANT PHARMOVA LIMITED
| Comapny Logo | Company | Client name | Buy/Sell | Qty Traded | Price | Trader Name |
|---|---|---|---|---|---|---|
 |
Kellton Tech Solutions Ltd. | Bofa Securities Europe Sa | BUY | 637K | 175.91 | Nk Securities Research Private Limited |
 |
JUBILANT PHARMOVA LIMITED | East Bridge Capital Master Fund Limited | SELL | 1M | 718.15 | East Bridge Capital Master Fund I Limited |
 |
Eris Lifesciences Limited | Franklin Templeton Mutual Fund | BUY | 1M | 1000.04 | Rakesh Shah |
The 637K shares of Kellton Tech Solutions Ltd. have been purchased by the by Bofa Securities Europe Sa through Foriegn Investments at a price of ₹175.91 per shareand it is sold by Nk Securities Research Private Limited at a price of ₹175.91 per shares.
The 1M shares of JUBILANT PHARMOVA LIMITED have been sold by the by East Bridge Capital Master Fund Limited through Foriegn Investments at a price of ₹718.15 per shareand it is purchased by East Bridge Capital Master Fund I Limited at a price of ₹718.15 per shares.
The 1M shares of Eris Lifesciences Limited have been purchased by the by Franklin Templeton Mutual Fund through Foriegn Investments at a price of ₹1000.04 per shareand it is sold by Rakesh Shah at a price of ₹1000.04 per shares.
Kellton Tech Solutions Ltd.
2.00
Net Sales
239.35
Net Profit
2.00
Total Income
-2.00
Expenditure
154
Current Price
1,499
Market Cap
In the most recent financial analysis for Kellton Tech Solutions Ltd., key metrics demonstrate a solid performance. The net sales reached ₹2.00 million, with total income amounting to ₹2.00 million. Expenditure was recorded at ₹-2.00 million, resulting in a net profit of ₹239.35 million. EPS figures for continuing operations are ₹2.50. Other notable figures include other income of ₹5.76 million, finance costs of ₹-46.82 million, and employee benefit expenses totaling ₹-1.00 million. Depreciation and amortization expenses were ₹-39.66 million, with current tax at ₹-9.93 million and deferred tax at ₹8.36 million. The total comprehensive income for the period was ₹246.72 million, and other comprehensive income net of taxes was ₹7.38 million.
With a market capitalization of ₹1,499 crore, the company’s stock is currently priced at ₹154. The historical trading range of the stock is ₹184 / 72.5. The P/E ratio is remarkably high at 21.9, suggesting a significant valuation. The book value stands at ₹45.5, and the dividend yield is 0.00%. The Return on Capital Employed (ROCE) is 16.2%, and the Return on Equity (ROE) is 15.7%. The debt-to-equity ratio is very low at 0.31, though the company shows a negative net cash flow of ₹-2.13 crore. The Piotroski score is 5.00, with the Graham Number pegged at ₹85.0. The Price-to-Book (P/B) ratio of 3.36 highlights a premium valuation.
Jubilant Pharmova Limited
17,317.00
Net Sales
4,818.00
Net Profit
17,457.00
Total Income
16,419.00
Expenditure
1,220
Current Price
19,424
Market Cap
The financial snapshot for Jubilant Pharmova Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹17,317.00 million and total income was ₹17,457.00 million. The company's expenditure was ₹16,419.00 million, leading to a net profit of ₹4,818.00 million. Earnings per Share (EPS) for continuing operations were ₹30.44. The report also highlights other income of ₹140.00 million, finance costs of ₹710.00 million, and employee benefit expenses of ₹5,529.00 million. Depreciation and amortization costs were ₹907.00 million, while current and deferred taxes were ₹261.00 million and ₹-82.00 million, respectively. The total comprehensive income for the period stood at ₹4,779.00 million, with other comprehensive income net of taxes at ₹-39.00 million.
With a market capitalization of ₹19,424 crore, the company’s stock is currently priced at ₹1,220. The historical trading range of the stock is ₹1,247 / 319. The P/E ratio is remarkably high at 83.0, suggesting a significant valuation. The book value stands at ₹341, and the dividend yield is 0.41%. The Return on Capital Employed (ROCE) is 6.74%, and the Return on Equity (ROE) is 0.76%. The debt-to-equity ratio is very low at 0.67, though the company shows a negative net cash flow of ₹-57.5 crore. The Piotroski score is 8.00, with the Graham Number pegged at ₹516. The Price-to-Book (P/B) ratio of 3.58 highlights a premium valuation.
Eris Lifesciences Limited
4,566.90
Net Sales
170.40
Net Profit
4,618.50
Total Income
4,350.30
Expenditure
1,448
Current Price
19,711
Market Cap
The latest financial figures for Eris Lifesciences Limited indicate a strong performance. The company achieved net sales of ₹4,566.90 million and total income of ₹4,618.50 million for the quarter. Expenditure was ₹4,350.30 million, resulting in a net profit of ₹170.40 million. Earnings per Share (EPS) for continuing operations stood at ₹1.25. The report also shows other income of ₹51.60 million, finance costs of ₹561.70 million, and employee benefit expenses of ₹1,037.50 million. Depreciation and amortization expenses totaled ₹455.50 million. Current tax expense was ₹46.90 million and deferred tax expense was ₹50.90 million. Total comprehensive income for the period was ₹163.20 million, with other comprehensive income net of taxes at ₹-7.20 million.
Currently valued at ₹19,711 crore, the company's stock price is ₹1,448. It has seen a price range of ₹1,522 / 792 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 52.2, implying a strong valuation. The book value per share is ₹190 and the dividend yield is 0.51%. ROCE is recorded at 11.3%, and ROE stands at 16.3%. The company maintains a very low debt-to-equity ratio of 1.08, though it has a negative net cash flow of ₹38.2 crore. The Piotroski score of 4.00 and the Graham Number of ₹346 suggest some caution, while the Price-to-Book (P/B) ratio of 7.62 reflects a premium valuation.
